Since Glaukos Corporation (NYSE:GKOS) and ENDRA Life Sciences Inc. (NASDAQ:NDRA) are part of the Medical Instruments & Supplies industry, they are influenced by compare. The influences particularly affect the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of both companies.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos Corporation	181.28M	15.63	12.95M	-0.39	0.00
ENDRA Life Sciences Inc.	N/A	1995.72	9.80M	-2.48	0.00

In table 1 we can see Glaukos Corporation and ENDRA Life Sciences Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us Glaukos Corporation and ENDRA Life Sciences Inc.?s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Glaukos Corporation	-7.14%	-3.9%	-3.3%
ENDRA Life Sciences Inc.	0.00%	-405.7%	-274.9%

Liquidity

The Current Ratio of Glaukos Corporation is 7.1 while its Quick Ratio stands at 6.5. The Current Ratio of rival ENDRA Life Sciences Inc. is 0.6 and its Quick Ratio is has 0.6. Glaukos Corporation is better equipped to clear short and long-term obligations than ENDRA Life Sciences Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Glaukos Corporation and ENDRA Life Sciences Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Glaukos Corporation	0	1	2	2.67
ENDRA Life Sciences Inc.	0	0	0	0.00

The downside potential is -3.02% for Glaukos Corporation with average price target of $76.

Insider & Institutional Ownership

Institutional investors owned 0% of Glaukos Corporation shares and 20.8% of ENDRA Life Sciences Inc. shares. Insiders owned roughly 0.3% of Glaukos Corporation’s shares. Insiders Comparatively, owned 3.2% of ENDRA Life Sciences Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Glaukos Corporation	-0.04%	7.05%	9.46%	8.64%	102.4%	21.58%
ENDRA Life Sciences Inc.	-1.13%	-16.67%	-48.22%	-31.03%	-42.43%	16.67%

For the past year Glaukos Corporation’s stock price has bigger growth than ENDRA Life Sciences Inc.

Summary

On 7 of the 10 factors Glaukos Corporation beats ENDRA Life Sciences Inc.

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

ENDRA Life Sciences Inc. develops photo- and thermo-acoustic medical technologies that bring new capabilities to existing ultrasound systems. Its photo-acoustic solutions help global medical researchers to screen and modify disease models with high image quality and volume scanning speed. The company offers the Nexus-128 system, a fully 3D imaging solution for imaging anatomy, physiology, and labeled molecular targets for institutions. Its thermo-acoustic technology is being developed to enable clinicians to use their existing ultrasound equipment to visualize tissue function, composition, and monitor various therapeutic interventions at the point of care. The company was incorporated in 2007 and is headquartered in Ann Arbor, Michigan.